Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model

Gene Therapy

Volumn 7, Issue 1, 2000, Pages 43-52

  Gomez Navarro J ^a   Contreras, J L ^b   Arafat, W ^a   Jiang, X L ^b   Krisky, D ^b   Oligino, T ^b   Marconi, P ^b   Hubbard, B ^b   Glorioso, J C ^b   Curiel, D T ^a   Thomas, J M ^b  

^a Gene Therapy Center   (United States)

^b Department of Surgery ^*  (United States)

Author keywords

Anti angiogenesis; CD34 cell; Gene transfer; Herpes simplex virus; Herpes simplex virus thymidine kinase; Rhesus monkey

Indexed keywords

CD34 ANTIGEN; GANCICLOVIR; GROWTH FACTOR; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA MODIFICATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HERPES VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; RHESUS MONKEY; SKIN AUTOGRAFT; SKIN NECROSIS; STEM CELL;

ANIMALIA; HERPES; HERPESVIRIDAE; MACACA MULATTA; PRIMATES; SIMPLEXVIRUS;

EID: 0343776138     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301054     Document Type: Article

References (61)

1. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90: 273-286.
2. Folkman J. Antiangiogenic gene therapy. Prof Natl Acad Sci USA 1998; 95: 9064-9066.
3. Kluth D. Inflammation, genes and gene therapy. JR Coll Phys Lond 1998; 32: 167-170.
4. Knechtle SJ, Zhai Y, Fechner J. Gene therapy in transplantation. Transplant Immunol 1996; 4: 257-264.
5. Anderson WF. Human gene therapy. Nature 1998; 392: 25-30.
6. Bilbao G, Gontreras JL, Gomez-Navarro J, Curiel DT. Improving adenoviral vectors for cancer gene therapy. Tumor Targeting 1998; 3: 59-79.
7. Thurston G et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101: 1401-1413.
8. Kay MA, Liu D, Hoogerbrugge PM. Gene therapy. Proc Natl Acad Sci USA 1997; 94: 12744-12746.
9. Vrancken PM, Perkins AL, Kay MA. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 1996; 20: 278-285.
10. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
11. Kafri T et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377-11382.
12. Paillard F. Mesothelial cells: the panacea for ex vivo gene therapy? Hum Gene Ther 1997; 8: 1839-1840.
13. Gage FH. Cell therapy. Nature 1998; 392: 18-24.
14. Smith A. Cell therapy: in search of pluripotency. Curr Biol 1998; 8: R802-R804.
15. Rancourt C et al. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. Clin Cancer Res 1998; 4: 265-270.
16. Asahara T et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
17. Shi Q et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-367.
18. Stump MM, Jordan GLJ, DeBakey ME, Halpert B. Endothelium grown from circulating blood on isolated intravascular Dacron hub. Am J Pathol 1963; 43: 361-363.
19. Gonzalez IE, Vermeulen F, Ehrenfeld WK. Relations between circulating blood and pathogenesis of atherosclerosis. Isr J Med Sci 1969; 5: 648-651.
20. Kennedy LJJ, Weissman IL. Dual origin of intimal cells in cardiac-allograft arteriosclerosis. New Engl J Med 1971; 285: 884-887.
21. Frazier OH, Baldwin RT, Eskin SG, Duncan JM. Immunochemical identification of human endothelial cells on the lining of a ventricular assist device. Tex Heart Inst J 1993; 20: 78-82.
22. Scott SM, Barth MG, Gaddy LR, Ahl ET Jr. The role of circulating cells in the healing of vascular prostheses. J Vasc Surg 1994; 19: 585-593.
23. Shi Q et al. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J Vasc Surg 1994; 20: 546-556.
24. Rafii S et al. Characterization of hematopoietic cells arising on the lextured surface of left ventricular assist devices. Ann Thorac Surg 1995; 60: 1627-1632.
25. Young PE, Baumhueter S, Lasky LA. The sialomucin CD34 is expressed on hematopoietic cells and blood vessels during murine development. Blood 1995; 85: 96-105.
26. Kabrun N et al. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 1997; 124: 2039-2048.
27. Eichmann A et al. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci USA 1997; 94: 5141-5146.
28. Shalaby F et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997; 89: 981-990.
29. Caprioli A et al. Blood-borne seeding by hematopoietic and endothelial precursors from the allantois. Proc Natl Acad Sci USA 1998; 95: 1641-1646.
30. Choi K et al. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725-732.
31. Hatzopoulos AK et al. Isolation and characterization of endothelial progenitor cells from mouse embryos. Development 1998; 125: 1457-1468.
32. Nishikawa SI et al. Progressive lineage analysis by cell sorting and culture identifies FLK1 + VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development 1998; 125: 1747-1757.
33. Labastie MC et al. Molecular identity of hematopoietic precursor cells emerging in the human embryo. Blood 1998; 92: 3624-3635.
34. Hirashima M, Kataoka H, Nishikawa S, Matsuyoshi N. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 1999; 93: 1253-1263.
35. Cleaver O, Krieg PA. VEGF mediates angioblast migration during development of the dorsal aorta in Xenopus. Development 1998; 125: 3905-3914.
36. Shalaby F et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
37. Medin JA, Karlsson S. Viral vectors for gene therapy of hematopoietic cells. Immunotechnology 1997; 3: 3-19.
38. Dunbar CE et al. Transduction of hematopoietic stem cells in humans and in nonhuman primates. Stem Cells 1997; 15 (Suppl 1): 135-139; discussion 139-140.
39. Havenga M, Hoogerbrugge P, Valerio D, van Es HH. Retroviral stem cell gene therapy. Stem Cells 1997; 15: 162-179.
40. Hennemann B et al. Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp Hematol 1999; 27: 817-825.
41. Douglas JT et al. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 1999; 17: 470-475.
42. Case SS et al. Stable transduction of quiescent CD34 (+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 1999; 96: 2988-2993.
43. Chatterjee S et al. Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Blood 1999; 93: 1882-1894.
44. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283: 682-686.
45. Briones J et al. Retroviral gene transfer into human hematopoietic cells: an in vitro kinetic study. Haematologica 1999; 84: 483-488.
46. Tisdale JF et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998; 92: 1131-1141.
47. Dilloo D et al. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 1997; 89: 119-127.
48. Watanabe T et al. Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors. Blood 1996; 87: 5032-5039.
49. Neering SJ et al. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood 1996; 88: 1147-1155.
50. Seth P et al. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res 1996; 56: 1346-1351.
51. +) using CMV driven adenoviral vectors (ad-v). Blood 1996; 88 (Suppl 1): 292b.
52. Garcia Sanchez F et al. Use of a safety recombinant adenovirus vector for selective bone marrow purging carrying the chemosensitization gene cytosine deaminase. International Society of Hematology, Charlottesville, VA, Carden Jennings, 1996, Abstr. 619: 1138.
53. Fu SQ, Garcia Sanchez F, Chung I, Deisseroth AB. Adenoviral vectors and hematopoietic cells. Blood 1997; 89: 1460-1467.
54. Frey BM et al. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors. Blood 1998; 91: 2781-2792.
55. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10; 4239-4242.
56. Springett GM et al. Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J Virol 1989; 63: 3865-3869.
57. Huard J et al. Gene transfer to muscle using herpes simplex virus-based vectors. Neuromusc Disord 1997; 7: 299-313.
58. Rachamim N et al. Potential role of CD34 stem cells in tolerance induction. Transplant Proc 1997; 29: 1935-1936.
59. Fiering SN et al. Improved FACS-Gal: flow cytometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs. Cytometry 1991; 12: 291-301.
60. Krisky, DM et al. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Therapy 1997; 4: 1120-1125.
61. Krisky DM et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Therapy 1998; 5: 1593-1603.